Clinical Trials Directory

Trials / Completed

CompletedNCT06224439

Comparison of Regional Anaesthesia Methods for Femoral Neck Fracture Surgery

Comparison of the Effectiveness of Lumbar Plexus Block and Unilateral Spinal Anaesthesia in Patients Undergoing Femoral Neck Fracture Surgery

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
300 (actual)
Sponsor
Bursa Yuksek Ihtisas Training and Research Hospital · Other Government
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

Femoral fracture surgery is frequently performed especially in geriatric population. Compared to general anaesthesia, regional anaesthesia is preferred to general anaesthesia in the geriatric patient population due to lower postoperative pulmonary complications, reduced frequency of delirium and analgesic requirement, intraoperative haemodynamic stability, early postoperative mobilisation and early discharge. Central and peripheral regional anaesthesia methods have advantages and disadvantages. This situation causes difficulties in the choice of anaesthesia method. Central regional anaesthesia techniques have more haemodynamic effects and higher frequency of complications compared to peripheral methods. The disadvantages of peripheral methods are that they require ultrasound, block needle, nerve stimulator and require knowledgeable and skilled practitioners. Since there is no study showing the comparison of peripheral nerve blocks and hypobaric spinal anaesthesia with objective nociception values and there are difficulties in the choice of anaesthesia method in this regard, a study was deemed necessary.

Conditions

Interventions

TypeNameDescription
PROCEDUREhypobaric spinal anaesthesia0.5% Bupivacain and distilled water with bupivacaine hydrochloride active ingredient will be applied in the range of 2-4cc according to the patient's height and weight.
PROCEDURElumbar plexus blockultrasound and nerve stimulator will be used for lumbar plexus block
PROCEDUREhyperbaric spinal anesthesia0.5% hyperbaric Bupivacain hydrochloride active ingredient will be applied in the range of 2-4cc according to the patient's height and weight.

Timeline

Start date
2024-01-25
Primary completion
2025-04-01
Completion
2025-04-13
First posted
2024-01-25
Last updated
2025-11-18

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT06224439. Inclusion in this directory is not an endorsement.